Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERVE-201 in Refractory Hyperlipidemia
NCT06451770Phase 1Recruiting
- Sponsor
- Verve Therapeutics
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
Phase 1, open-label trial of VERVE-201 in hypercholesterolemia and Refractory hypertriglyceridemia (rHTG) (3 arms), sponsored by Verve Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) at 365 days. Started Oct 2024; status: recruiting.
02
Drugs
VERVE-201
03
Conditions
hypercholesterolemiaRefractory hypertriglyceridemia (rHTG)
Beyond the preview
Go deeper on NCT06451770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06451770.